Cirsium Biosciences

Cirsium Biosciences is a biotechnology company democratizing gene therapy through transformative plant-based viral vector production methods. The company uses whole plants as bioreactors to produce recombinant AAV vectors, enabling highly scalable, rapid, and cost-effective manufacturing that significantly reduces lead times and batch failures compared to traditional cGMP facilities. Founded by CEO Daniel Gibbs, who brings 20+ years of viral vector and gene therapy expertise, Cirsium is addressing critical industry bottlenecks including inadequate global production capacity, poor scalability, and prohibitively high manufacturing costs. The company is headquartered in San Diego, California and has raised more than $10 million from top investors.